Accelerating drug development by early unwanted immunogenicity testing

Accelerating drug development by early unwanted immunogenicity testing

About the webinar

Complex immune responses elicited upon treatment with biotherapeutic drugs are now revolutionizing the field of immuno-oncology. However, unwanted immune responses exerted by biologics can result in severe adverse effects. Immunogenicity testing at the early phase of drug development therefore can play a crucial role to avoid possible clinical consequences of anti-drug antibody (ADA) responses. Testing unwanted immune responses during drug development is becoming increasingly important for pharmaceutical industries and regulatory agencies like the FDA and EMEA.   

This webinar covers:  

  • Causes and consequences of unwanted immunogenicity
  • In vitro cellular assays to assess unwanted immunogenicity, including T cell activation/proliferation and MAPPS (MHC-associated peptide proteomics) assays
  • Strategies to manage and reduce unwanted immune responses

Presenter
 

Sofie Pattijn, Ph.D.

CTO at ImmunXperts SA, a service provider for drug development processes

Watch the complete webinar for free

Your Miltenyi University benefits

Access online courses anytime, anywhere.

Become an expert in standard and innovative applications.

Acquire broad expertise and a comprehensive skill set.

Let us know your thoughts!

You did not find the course you are looking for? 
Do you have questions or comments? 
Drop us an e-mail!